Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis

Journal of Cystic Fibrosis

Volumn 12, Issue 6, 2013, Pages 688-699

  Reid, D W ^a,b,c   Latham, R ^a,d   Lamont, I L ^e   Camara, M ^f   Roddam, L F ^d  

^a UNIVERSITY OF TASMANIA   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c THE PRINCE CHARLES HOSPITAL   (Australia)

^d UNIVERSITY OF TASMANIA   (Australia)

^e UNIVERSITY OF OTAGO   (New Zealand)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; COMPLEMENTARY DNA; CORTICOSTEROID; DNA TOPOISOMERASE (ATP HYDROLYSING) B; GENOMIC DNA; MONOBACTAM DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ASPERGILLUS FUMIGATUS; BACTERIAL CELL; BACTERIAL LOAD; BACTERIUM CULTURE; BODY MASS; BURKHOLDERIA CEPACIA COMPLEX; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTIC FIBROSIS; DISEASE EXACERBATION; ENZYME ACTIVATION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HAEMOPHILUS INFLUENZAE; HUMAN; LUNG FUNCTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MISMATCH REPAIR; MOLECULAR DYNAMICS; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA ISOLATION; SCORING SYSTEM; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THORAX PAIN; TREATMENT DURATION;

ADOLESCENT; ADULT; COLONY COUNT, MICROBIAL; CYSTIC FIBROSIS; DISEASE PROGRESSION; DNA, BACTERIAL; FEMALE; HUMANS; LUNG; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY FUNCTION TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPUTUM; YOUNG ADULT;

EID: 84888028566     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2013.03.008     Document Type: Article

References (41)

1. Reid D.W., Blizzard C.L., Shugg D.M., Flowers C., Cash C., Greville H.M. Changes in cystic fibrosis mortality in Australia, 1979-2005. Med J Aust 2011, 195(7):392-395.
2. Dodge J.A., Lewis P.A., Stanton M., Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007, 29(3):522-526.
3. Sanders D.B., Bittner R.C., Rosenfeld M., Redding G.J., Goss C.H. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011, 46(4):393-400.
4. Konstan M.W., Morgan W.J., Butler S.M., Pasta D.J., Craib M.L., Silva S.J., et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007, 151(2):134-139. (9 e1).
5. Amadori A., Antonelli A., Balteri I., Schreiber A., Bugiani M., De Rose V. Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis. Respir Med 2009, 103(3):407-413.
6. Armstrong D., Grimwood K., Carlin J.B., Carzino R., Hull J., Olinsky A., et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol 1998, 26(6):371-379.
7. Clifton I.J., Kastelik J.A., Peckham D.G., Hale A., Denton M., Etherington C., et al. Ten years of viral and non-bacterial serology in adults with cystic fibrosis. Epidemiol Infect 2008, 136(1):128-134.
8. Gray R.D., MacGregor G., Noble D., Imrie M., Dewar M., Boyd A.C., et al. Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med 2008, 178(5):444-452.
9. Hannauer M., Yeterian E., Martin L.W., Lamont I.L., Schalk I.J. An efflux pump is involved in secretion of newly synthesized siderophore by Pseudomonas aeruginosa. FEBS Lett 2010, 584(23):4751-4755.
10. Stressmann F.A., Rogers G.B., Marsh P., Lilley A.K., Daniels T.W., Carroll M.P., et al. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?. J Cyst Fibros 2011, 10(5):357-365.
11. Parkins M.D., Rendall J.C., Elborn J.S. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 2012, 141(2):485-493.
12. Padoan R., Brienza A., Crossignani R.M., Lodi G., Giunta A., Assael B.M., et al. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis. J Pediatr 1983, 103(2):320-324.
13. Beaudry P.H., Marks M.I., McDougall D., Desmond K., Rangel R. Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?. J Pediatr 1980, 97(1):144-147.
14. Regelmann W.E., Elliott G.R., Warwick W.J., Clawson C.C. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990, 141(4 Pt 1):914-921.
15. Smith B.R. Cefsulodin and ceftazidime, two antipseudomonal cephalosporins. Clin Pharm 1984, 3(4):373-385.
16. Tunney M.M., Field T.R., Moriarty T.F., Patrick S., Doering G., Muhlebach M.S., et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008, 177(9):995-1001.
17. Sibley C.D., Parkins M.D., Rabin H.R., Duan K., Norgaard J.C., Surette M.G. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci USA 2008, 105(39):15070-15075.
18. Rogers G.B., Stressmann F.A., Walker A.W., Carroll M.P., Bruce K.D. Lung infections in cystic fibrosis: deriving clinical insight from microbial complexity. Expert Rev Mol Diagn 2010, 10(2):187-196.
19. CLSI Clinical and Laboratory Standards Institute; performance standards for antimicrobial susceptibility testing M100-S17 2009, 27. 19th Informational Supplement., 19th Informational Supplement:M100-S17.
20. Martin L.W., Reid D.W., Sharples K.J., Lamont I.L. Pseudomonas siderophores in the sputum of patients with cystic fibrosis. Biometals 2011, 24(6):1059-1067.
21. Wood-Baker R., Tristram S., Latham R., Haug G., Reid D., Roddam L.F. Molecular detection of Haemophilus influenzae in COPD sputum is superior to conventional culturing methods. Br J Biomed Sci 2012, 69(1):37-39.
22. Matsuda K., Tsuji H., Asahara T., Kado Y., Nomoto K. Sensitive quantitative detection of commensal bacteria by rRNA-targeted reverse transcription-PCR. Appl Environ Microbiol 2007, 73(1):32-39.
23. Uzuka R., Kawashima H., Hasegawa D., Ioi H., Amaha M., Kashiwagi Y., et al. Rapid diagnosis of bacterial meningitis by using multiplex PCR and real time PCR. Pediatr Int 2004, 46(5):551-554.
24. Avrain L., Garvey M., Mesaros N., Glupczynski Y., Mingeot-Leclercq M.P., Piddock L.J., et al. Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations. J Antimicrob Chemother 2007, 60(5):965-972.
25. Goerke C., Fluckiger U., Steinhuber A., Zimmerli W., Wolz C. Impact of the regulatory loci agr, sarA and sae of Staphylococcus aureus on the induction of alpha-toxin during device-related infection resolved by direct quantitative transcript analysis. Mol Microbiol 2001, 40(6):1439-1447.
26. Bauernfeind A., Schneider I., Jungwirth R., Roller C. Discrimination of Burkholderia multivorans and Burkholderia vietnamiensis from Burkholderia cepacia genomovars I, III, and IV by PCR. J Clin Microbiol 1999, 37(5):1335-1339.
27. Challier S., Boyer S., Abachin E., Berche P. Development of a serum-based Taqman real-time PCR assay for diagnosis of invasive aspergillosis. J Clin Microbiol 2004, 42(2):844-846.
28. Davis S.D., Brody A.S., Emond M.J., Brumback L.C., Rosenfeld M. Endpoints for clinical trials in young children with cystic fibrosis. Proc Am Thorac Soc 2007, 4(4):418-430.
29. Draper R.C., Martin L.W., Beare P.A., Lamont I.L. Differential proteolysis of sigma regulators controls cell-surface signalling in Pseudomonas aeruginosa. Mol Microbiol 2011, 82(6):1444-1453.
30. de Boer K., Vandemheen K.L., Tullis E., Doucette S., Fergusson D., Freitag A., et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011, 66(8):680-685.
31. Wolter J.M., Bowler S.D., McCormack J.G. Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis?. Aust N Z J Med 1999, 29(1):15-21.
32. Reid D.W., Lam Q.T., Schneider H., Walters E.H. Airway iron and iron-regulatory cytokines in cystic fibrosis. Eur Respir J 2004, 24(2):286-291.
33. Aaron S.D., Vandemheen K.L., Ferris W., Fergusson D., Tullis E., Haase D., et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005, 366(9484):463-471. (6-12).
34. Keays T., Ferris W., Vandemheen K.L., Chan F., Yeung S.W., Mah T.F., et al. A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations. J Cyst Fibros 2009, 8(2):122-127.
35. Reid D.W., Misso N., Aggarwal S., Thompson P.J., Walters E.H. Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis. Respirology 2007, 12(1):63-69.
36. Wong A.W., Gan W.Q., Burns J., Sin D.D., van Eeden S.F. Acute exacerbation of chronic obstructive pulmonary disease: influence of social factors in determining length of hospital stay and readmission rates. Can Respir J 2008, 15(7):361-364.
37. Tunney M.M., Klem E.R., Fodor A.A., Gilpin D.F., Moriarty T.F., McGrath S.J., et al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 2011, 66(7):579-584.
38. Worlitzsch D., Rintelen C., Bohm K., Wollschlager B., Merkel N., Borneff-Lipp M., et al. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin Microbiol Infect 2009, 15(5):454-460.
39. Rogers G.B., Marsh P., Stressmann A.F., Allen C.E., Daniels T.V., Carroll M.P., et al. The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples. Clin Microbiol Infect 2010, 16(11):1656-1658.
40. Lysenko E.S., Clarke T.B., Shchepetov M., Ratner A.J., Roper D.I., Dowson C.G., et al. Nod1 signaling overcomes resistance of S. pneumoniae to opsonophagocytic killing. PLoS Pathog 2007, 3(8):e118.
41. Margolis E., Yates A., Levin B.R. The ecology of nasal colonization of Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus: the role of competition and interactions with host's immune response. BMC Microbiol 2010, 10:59.